Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friederike Mackensen

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Current Opinion in Ophthalmology|September 16, 2009
Tubulointerstitial nephritis and uveitis syndromeFriederike Mackensen, Heiko Billing
Current Opinion in Ophthalmology|September 15, 2015
Ocular toxoplasmosis: background and evidence for an antibiotic prophylaxisMichael Reich, Friederike Mackensen
The British Journal of Ophthalmology|July 12, 2015
Influence of drug therapy on the risk of recurrence of ocular toxoplasmosisMichael Reich, Matthias D Becker, Friederike Mackensen
Clinical Ophthalmology (Auckland, N.Z.)|November 10, 2009
Interferons and their potential in the treatment of ocular inflammationFriederike Mackensen, Regina Max, Matthias D Becker
Current Opinion in Ophthalmology|October 27, 2006
Interferon therapy for ocular diseaseFriederike Mackensen, Regina Max, Matthias D Becker
Ophthalmology|March 27, 2007
Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndromeFriederike Mackensen, Justine R Smith, James T Rosenbaum
Nature Clinical Practice. Rheumatology|March 31, 2007
Therapy insight: scleritis and its relationship to systemic autoimmune diseaseJustine R Smith, Friederike Mackensen, James T Rosenbaum
Deutsches Arzteblatt International|September 16, 2014
Ocular changes during pregnancyFriederike Mackensen, Wolfgang E Paulus, Regina Max, et al.
Retina (Philadelphia, Pa.)|January 11, 2008
Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot studyFriederike Mackensen, Carsten Heinz, Matthias D Becker, et al.
Retina (Philadelphia, Pa.)|October 10, 2014
Time patterns of recurrences and factors predisposing for a higher risk of recurrence of ocular toxoplasmosisMichael Reich, Mira Ruppenstein, Matthias D Becker, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Current Opinion in Ophthalmology|September 16, 2009
Tubulointerstitial nephritis and uveitis syndromeFriederike Mackensen, Heiko Billing
Current Opinion in Ophthalmology|September 15, 2015
Ocular toxoplasmosis: background and evidence for an antibiotic prophylaxisMichael Reich, Friederike Mackensen
The British Journal of Ophthalmology|July 12, 2015
Influence of drug therapy on the risk of recurrence of ocular toxoplasmosisMichael Reich, Matthias D Becker, Friederike Mackensen
Clinical Ophthalmology (Auckland, N.Z.)|November 10, 2009
Interferons and their potential in the treatment of ocular inflammationFriederike Mackensen, Regina Max, Matthias D Becker
Current Opinion in Ophthalmology|October 27, 2006
Interferon therapy for ocular diseaseFriederike Mackensen, Regina Max, Matthias D Becker
Ophthalmology|March 27, 2007
Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndromeFriederike Mackensen, Justine R Smith, James T Rosenbaum
Nature Clinical Practice. Rheumatology|March 31, 2007
Therapy insight: scleritis and its relationship to systemic autoimmune diseaseJustine R Smith, Friederike Mackensen, James T Rosenbaum
Deutsches Arzteblatt International|September 16, 2014
Ocular changes during pregnancyFriederike Mackensen, Wolfgang E Paulus, Regina Max, et al.
Retina (Philadelphia, Pa.)|January 11, 2008
Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot studyFriederike Mackensen, Carsten Heinz, Matthias D Becker, et al.
Retina (Philadelphia, Pa.)|October 10, 2014
Time patterns of recurrences and factors predisposing for a higher risk of recurrence of ocular toxoplasmosisMichael Reich, Mira Ruppenstein, Matthias D Becker, et al.
Pageof 5